3.4 UL21.5 mRNA in plasma of patients developing drug resistance
or self-resolving DNAemia blips during LTV/MBV treatment.
UL21.5 mRNA was tested in four plasma samples collected from patients
(KTR and HSCTR) developing drug-resistant HCMV infection during LTV
prophylaxis or MBV treatment. The mRNA was detected in the four samples
analysed at levels between 60 and 586 copies/ml. In parallel, plasma
samples from four HSCTR and one KTR showing transient self-resolving
DNAemia blips during LTV prophylaxis were also analysed. UL21.5 mRNA was
undetectable in all the 5 samples tested (Fig 5).